首页 > 最新文献

Progress in cardiovascular diseases最新文献

英文 中文
Sudden cardiac arrest: Limitations in risk-stratification and treatment, and the potential for digital technologies and artificial intelligence to improve prediction and outcomes 心脏骤停:风险分层和治疗的局限性,以及数字技术和人工智能改善预测和结果的潜力。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.06.005
Sudarshan Srivats , Fawzi Zghyer , Zaid Shahrori , Christine Albert , Sana M. Al-Khatib , Sumeet Chugh , Susan P. Etheridge , Zachary D. Goldberger , Rakesh Gopinathannair , Dhanunjaya Lakkireddy , Daniel P. Morin , Marco V. Perez , Markus Rottmann , Jacob E. Sunshine , Paul J. Wang , Mina K. Chung
Sudden cardiac death (SCD) remains a pervasive public health challenge, accounting for a significant proportion of cardiac and all-cause mortality worldwide. Despite notable advancements in cardiovascular therapies and reductions in overall cardiac mortality, survival following sudden cardiac arrest (SCA) remains dismally low, and prediction strategies remain inadequate. This comprehensive review examines the current landscape of SCD etiologies and the latest guidelines for primary and secondary prevention of SCD with implantable cardioverter defibrillators (ICDs). Particular attention is given to the limitations of left ventricular ejection fraction (LVEF) as the primary tool for risk stratification, given its low sensitivity, specificity, and limited applicability to the broader population in which most SCDs occur. Emerging risk scores and machine learning (ML) driven prediction models have begun to efficiently integrate clinical, electrical, imaging, genetic and laboratory parameters to improve SCD risk stratification. This review highlights examples of such artificial intelligence (AI) prediction models and discusses their potential role in the near-term and long-term prediction of SCD in both in-hospital and out-of-hospital settings, while emphasizing the need for external validation of such models. The review also discusses critical system-level gaps in the chain of survival from cardiac arrest, particularly the need for automated emergency medical services (EMS) activation, community responder engagement, high-quality cardiopulmonary resuscitation (CPR) and improved access to defibrillation. It explores the role of digital technologies such as wearable sensors, smartwatches, smartphone applications and implantable devices in improving real-time SCA detection and enhancing early aspects of the chain of survival from cardiac arrest. Finally, the review calls for a multidisciplinary, multi-sectoral approach including regulatory, technological, and public health stakeholders to bridge gaps in SCD prevention, detection, and response.
心源性猝死(SCD)仍然是一个普遍存在的公共卫生挑战,占全球心脏和全因死亡的很大比例。尽管心血管治疗取得了显著进步,心脏总死亡率降低,但心脏骤停(SCA)后的生存率仍然低得令人沮丧,预测策略仍然不足。本文综述了SCD病因学的现状,以及植入式心律转复除颤器(ICDs)一级和二级预防SCD的最新指南。鉴于左室射血分数(LVEF)的低敏感性、特异性和对大多数SCDs发生的更广泛人群的有限适用性,我们特别关注了LVEF作为风险分层主要工具的局限性。新兴的风险评分和机器学习(ML)驱动的预测模型已经开始有效地整合临床、电气、成像、遗传和实验室参数,以改善SCD风险分层。本综述重点介绍了此类人工智能(AI)预测模型的示例,并讨论了它们在院内和院外SCD近期和长期预测中的潜在作用,同时强调了对此类模型进行外部验证的必要性。该综述还讨论了心脏骤停后生存链中关键的系统级差距,特别是对自动紧急医疗服务(EMS)激活、社区响应者参与、高质量心肺复苏(CPR)和改善除颤可及性的需求。它探讨了数字技术的作用,如可穿戴传感器、智能手表、智能手机应用程序和植入式设备,在改善实时SCA检测和增强心脏骤停生存链的早期方面。最后,审查报告呼吁采取包括监管、技术和公共卫生利益攸关方在内的多学科、多部门方法,弥合SCD预防、检测和应对方面的差距。
{"title":"Sudden cardiac arrest: Limitations in risk-stratification and treatment, and the potential for digital technologies and artificial intelligence to improve prediction and outcomes","authors":"Sudarshan Srivats ,&nbsp;Fawzi Zghyer ,&nbsp;Zaid Shahrori ,&nbsp;Christine Albert ,&nbsp;Sana M. Al-Khatib ,&nbsp;Sumeet Chugh ,&nbsp;Susan P. Etheridge ,&nbsp;Zachary D. Goldberger ,&nbsp;Rakesh Gopinathannair ,&nbsp;Dhanunjaya Lakkireddy ,&nbsp;Daniel P. Morin ,&nbsp;Marco V. Perez ,&nbsp;Markus Rottmann ,&nbsp;Jacob E. Sunshine ,&nbsp;Paul J. Wang ,&nbsp;Mina K. Chung","doi":"10.1016/j.pcad.2025.06.005","DOIUrl":"10.1016/j.pcad.2025.06.005","url":null,"abstract":"<div><div>Sudden cardiac death (SCD) remains a pervasive public health challenge, accounting for a significant proportion of cardiac and all-cause mortality worldwide. Despite notable advancements in cardiovascular therapies and reductions in overall cardiac mortality, survival following sudden cardiac arrest (SCA) remains dismally low, and prediction strategies remain inadequate. This comprehensive review examines the current landscape of SCD etiologies and the latest guidelines for primary and secondary prevention of SCD with implantable cardioverter defibrillators (ICDs). Particular attention is given to the limitations of left ventricular ejection fraction (LVEF) as the primary tool for risk stratification, given its low sensitivity, specificity, and limited applicability to the broader population in which most SCDs occur. Emerging risk scores and machine learning (ML) driven prediction models have begun to efficiently integrate clinical, electrical, imaging, genetic and laboratory parameters to improve SCD risk stratification. This review highlights examples of such artificial intelligence (AI) prediction models and discusses their potential role in the near-term and long-term prediction of SCD in both in-hospital and out-of-hospital settings, while emphasizing the need for external validation of such models. The review also discusses critical system-level gaps in the chain of survival from cardiac arrest, particularly the need for automated emergency medical services (EMS) activation, community responder engagement, high-quality cardiopulmonary resuscitation (CPR) and improved access to defibrillation. It explores the role of digital technologies such as wearable sensors, smartwatches, smartphone applications and implantable devices in improving real-time SCA detection and enhancing early aspects of the chain of survival from cardiac arrest. Finally, the review calls for a multidisciplinary, multi-sectoral approach including regulatory, technological, and public health stakeholders to bridge gaps in SCD prevention, detection, and response.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 144-166"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart rate variability in patients with cardiovascular diseases 心血管疾病患者的心率变异性。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.06.003
Muhammad Shahzeb Khan , Syed Sarmad Javaid , Robert J. Mentz , JoAnn Lindenfeld , Hau-Tieng Wu , Jürgen H. Prochaska , Jens Brock Johansen , Philipp S. Wild , Dominik Linz , Wilfried Dinh , Marat Fudim
Heart rate variability (HRV) has been reported to predict overall mortality and the risk of cardiovascular disease events in patients, including those with heart failure. However, inconsistent methods of recording and analyzing HRV parameters, along with a lack of randomized data substantiating its clinical efficacy and potential to guide treatment decisions for improved patient outcomes, have limited its use in clinical settings. With the advancements in technologies such as artificial intelligence and machine learning, and emergence of ablation procedures that can alter autonomic function, this article re-explores HRV assessment methods, their potential for clinical application, the issues encountered in using them in clinical research, and potential approaches to studying HRV in the future (Graphical Abstract).
据报道,心率变异性(HRV)可预测患者的总体死亡率和心血管疾病事件的风险,包括心力衰竭患者。然而,记录和分析HRV参数的方法不一致,加上缺乏随机数据证实其临床疗效和指导治疗决策以改善患者预后的潜力,限制了其在临床环境中的应用。随着人工智能和机器学习等技术的进步,以及可以改变自主神经功能的消融手术的出现,本文重新探讨了HRV评估方法、临床应用潜力、临床研究中遇到的问题以及未来HRV研究的潜在途径(图形摘要)。
{"title":"Heart rate variability in patients with cardiovascular diseases","authors":"Muhammad Shahzeb Khan ,&nbsp;Syed Sarmad Javaid ,&nbsp;Robert J. Mentz ,&nbsp;JoAnn Lindenfeld ,&nbsp;Hau-Tieng Wu ,&nbsp;Jürgen H. Prochaska ,&nbsp;Jens Brock Johansen ,&nbsp;Philipp S. Wild ,&nbsp;Dominik Linz ,&nbsp;Wilfried Dinh ,&nbsp;Marat Fudim","doi":"10.1016/j.pcad.2025.06.003","DOIUrl":"10.1016/j.pcad.2025.06.003","url":null,"abstract":"<div><div>Heart rate variability (HRV) has been reported to predict overall mortality and the risk of cardiovascular disease events in patients, including those with heart failure. However, inconsistent methods of recording and analyzing HRV parameters, along with a lack of randomized data substantiating its clinical efficacy and potential to guide treatment decisions for improved patient outcomes, have limited its use in clinical settings. With the advancements in technologies such as artificial intelligence and machine learning, and emergence of ablation procedures that can alter autonomic function, this article re-explores HRV assessment methods, their potential for clinical application, the issues encountered in using them in clinical research, and potential approaches to studying HRV in the future (Graphical Abstract).</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 67-79"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardioneuroablation: Three different approaches 心脏神经消融术:三种不同的方法。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.04.003
Medhat Farwati , Tolga Aksu , Enrique I. Pachon , Tomas Santillana , Carlos Thiene Pachon , Pasquale Santangeli , Jose Carlos Pachon
Cardioneuroablation (CNA) is an emerging therapy for patients with vasovagal syncope with predominant cardioinhibitory responses. The procedure targets the neuromyocardial connections localized in specific regions of the right and left atrium as well as the adjacent ganglionated plexi (GP) providing parasympathetic innervation to the sinus and atrioventricular nodes. The target regions for CNA can be determined with various techniques, which result in heterogenous procedural approaches and endpoints in different centers specialized in this procedure. In this review we summarize the rationale and details of the procedural approach for three different techniques for CNA, namely: CNA controlled by extra-cardiac vagal stimulation, CNA guided by analysis of fractionated electrograms, and an anatomical approach to CNA.
心血管消融术(CNA)是一种新兴的治疗血管迷走神经性晕厥的主要心脏抑制反应。该手术的目标是位于左右心房特定区域的神经心肌连接,以及相邻的神经节丛(GP),为窦和房室结提供副交感神经支配。CNA的目标区域可以通过各种技术确定,这导致不同的程序方法和不同中心的端点专门从事该过程。在这篇综述中,我们总结了三种不同的CNA技术的基本原理和细节,即:由心外迷走神经刺激控制的CNA,由分频电图分析指导的CNA,以及CNA的解剖入路。
{"title":"Cardioneuroablation: Three different approaches","authors":"Medhat Farwati ,&nbsp;Tolga Aksu ,&nbsp;Enrique I. Pachon ,&nbsp;Tomas Santillana ,&nbsp;Carlos Thiene Pachon ,&nbsp;Pasquale Santangeli ,&nbsp;Jose Carlos Pachon","doi":"10.1016/j.pcad.2025.04.003","DOIUrl":"10.1016/j.pcad.2025.04.003","url":null,"abstract":"<div><div><span><span>Cardioneuroablation (CNA) is an emerging therapy for patients with vasovagal syncope with predominant cardioinhibitory responses. The procedure targets the neuromyocardial connections localized in specific regions of the right and left atrium<span> as well as the adjacent ganglionated plexi (GP) providing parasympathetic innervation to the sinus and </span></span>atrioventricular nodes. The target regions for CNA can be determined with various techniques, which result in heterogenous procedural approaches and endpoints in different centers specialized in this procedure. In this review we summarize the rationale and details of the procedural approach for three different techniques for CNA, namely: CNA controlled by extra-cardiac vagal stimulation, CNA guided by analysis of fractionated </span>electrograms, and an anatomical approach to CNA.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 80-89"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies for optimizing efficacy of electrical cardioversion of atrial fibrillation 优化心房颤动电复律疗效的策略。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.06.009
Sahil Bharwani , Mina K. Chung , Daniel P. Morin
Direct current cardioversion (DCCV) is a cornerstone in the management of atrial fibrillation (AF) and is the quickest way to convert AF to sinus rhythm. Overall, the procedure is effective and safe, but the efficacy of DCCV can be reduced due to modifiable and non-modifiable patient characteristics, or procedural factors. Additionally, inadequate preparation, such as a lack of QRS-synchronization or omitting preprocedural imaging of the left atrial appendage (LAA), could lead to significant harm. This manuscript discusses a brief history of electrical cardioversion, the currently available cardioverter settings/configuration with the highest success rate, the common barriers to successful cardioversion, strategies to overcome these barriers, and suggested protocols to ensure a high level of patient safety.
直流电复律(DCCV)是房颤(AF)治疗的基石,是将房颤转化为窦性心律的最快方法。总的来说,该手术是有效和安全的,但DCCV的疗效可能会因可改变或不可改变的患者特征或手术因素而降低。此外,不充分的准备,如缺乏qrs同步或遗漏左心耳(LAA)的术前成像,可能导致严重的伤害。本文讨论了电复律的简史,目前可用的成功率最高的复律设置/配置,成功复律的常见障碍,克服这些障碍的策略,以及确保高水平患者安全的建议方案。
{"title":"Strategies for optimizing efficacy of electrical cardioversion of atrial fibrillation","authors":"Sahil Bharwani ,&nbsp;Mina K. Chung ,&nbsp;Daniel P. Morin","doi":"10.1016/j.pcad.2025.06.009","DOIUrl":"10.1016/j.pcad.2025.06.009","url":null,"abstract":"<div><div><span>Direct current </span>cardioversion<span><span><span> (DCCV) is a cornerstone in the management of atrial fibrillation<span> (AF) and is the quickest way to convert AF to sinus rhythm. Overall, the procedure is effective and safe, but the efficacy of DCCV can be reduced due to modifiable and non-modifiable </span></span>patient characteristics, or procedural factors. Additionally, inadequate preparation, such as a lack of QRS-synchronization or omitting preprocedural imaging of the left atrial appendage (LAA), could lead to significant harm. This manuscript discusses a brief history of electrical cardioversion, the currently available cardioverter settings/configuration with the highest success rate, the common barriers to successful cardioversion, strategies to overcome these barriers, and suggested protocols to ensure a high level of </span>patient safety.</span></div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 18-27"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of contact force and pulsed field ablation parameters on myocardial lesion formation during pulsed field ablation: A systematic review of pre-clinical studies 接触力和脉冲场消融参数对脉冲场消融过程中心肌病变形成的影响:临床前研究的系统回顾。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.07.001
Jacopo Marazzato , Fengwei Zou , Marco Schiavone , Vincenzo Mirco La Fazia , Giovanni Forleo , Sanghamitra Mohanty , Aung Lin , Domingo Ynoa Garcia , Andrea Natale , Xiaodong Zhang , Luigi Di Biase
Pulsed field ablation (PFA) is a novel and minimally thermal energy source that exploits the biophysics of irreversible electroporation (IRE) to cause cell death. Differently from radiofrequency ablation (RFA) where adequate catheter-tissue contact proved paramount in lesion formation, the additional role of contact force (CF) during PFA is under debate due to the inherent myocardial selectivity and the customizable nature of IRE. In fact, it is not clear whether the amount of contact exerted during PFA delivery is as pivotal in achieving optimal lesion size as during RFA. Moreover, the variety of PFA catheters and the myriads of IRE ablation settings available would further potentially limit the role of CF in this scenario. However, beyond CF, specific ablation parameters, such as the PFA dose, number of pulses, catheter tip orientation and specific PFA workflows, proved to act in synergy with CF in achieving wide and deep ablation lesions even during PFA delivery. Therefore, the aim of this systematic review is to provide a better understanding on which ablation parameters – CF included - can help to obtain effective lesion formation during PFA.
脉冲场烧蚀(PFA)是一种利用不可逆电穿孔(IRE)的生物物理特性导致细胞死亡的新型低热能源。与射频消融术(RFA)不同,充分的导管与组织接触在病变形成中被证明是至关重要的,由于固有的心肌选择性和IRE的可定制性,PFA期间接触力(CF)的额外作用正在争论中。事实上,目前尚不清楚在PFA输送过程中施加的接触量是否与RFA过程中达到最佳病变大小一样关键。此外,各种各样的PFA导管和无数可用的IRE消融设置将进一步限制CF在这种情况下的作用。然而,除了CF,特定的消融参数,如PFA剂量、脉冲数、导管尖端方向和特定的PFA工作流程,被证明与CF协同作用,即使在PFA输送过程中也能实现广泛和深度的消融病变。因此,本系统综述的目的是提供更好的理解消融参数-包括CF -可以帮助在PFA期间获得有效的病变形成。
{"title":"Impact of contact force and pulsed field ablation parameters on myocardial lesion formation during pulsed field ablation: A systematic review of pre-clinical studies","authors":"Jacopo Marazzato ,&nbsp;Fengwei Zou ,&nbsp;Marco Schiavone ,&nbsp;Vincenzo Mirco La Fazia ,&nbsp;Giovanni Forleo ,&nbsp;Sanghamitra Mohanty ,&nbsp;Aung Lin ,&nbsp;Domingo Ynoa Garcia ,&nbsp;Andrea Natale ,&nbsp;Xiaodong Zhang ,&nbsp;Luigi Di Biase","doi":"10.1016/j.pcad.2025.07.001","DOIUrl":"10.1016/j.pcad.2025.07.001","url":null,"abstract":"<div><div>Pulsed field ablation (PFA) is a novel and minimally thermal energy source that exploits the biophysics of irreversible electroporation (IRE) to cause cell death. Differently from radiofrequency ablation (RFA) where adequate catheter-tissue contact proved paramount in lesion formation, the additional role of contact force (CF) during PFA is under debate due to the inherent myocardial selectivity and the customizable nature of IRE. In fact, it is not clear whether the amount of contact exerted during PFA delivery is as pivotal in achieving optimal lesion size as during RFA. Moreover, the variety of PFA catheters and the myriads of IRE ablation settings available would further potentially limit the role of CF in this scenario. However, beyond CF, specific ablation parameters, such as the PFA dose, number of pulses, catheter tip orientation and specific PFA workflows, proved to act in synergy with CF in achieving wide and deep ablation lesions even during PFA delivery. Therefore, the aim of this systematic review is to provide a better understanding on which ablation parameters – CF included - can help to obtain effective lesion formation during PFA.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 49-61"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
List of recent issues 近期刊物一览表
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/S0033-0620(25)00121-5
{"title":"List of recent issues","authors":"","doi":"10.1016/S0033-0620(25)00121-5","DOIUrl":"10.1016/S0033-0620(25)00121-5","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Page A3"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulsed field ablation: The basics relating to effectiveness, durability, and safety 脉冲场消融:与有效性、耐久性和安全性相关的基础知识。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.05.007
Sara Vázquez-Calvo, Deepti Ranganathan, Atul Verma
Pulsed field ablation (PFA) represents an innovative energy delivery approach for cardiac arrhythmia treatment, characterized by a favorable safety profile and effective myocardial lesion formation. It has demonstrated high acute pulmonary vein isolation rates with a reduced incidence of injury to adjacent anatomical structures. Nonetheless, procedure-specific complications such as haemolysis, intravascular gas formation, and coronary vasospasm have been observed and warrant further evaluation. Clinical evidence supports efficacy comparable to conventional thermal ablation in terms of arrhythmia recurrence. Ongoing advancements in catheter engineering, pulse modulation, and multimodal energy strategies aim to enhance lesion durability and transmurality. These developments position PFA as a promising technology in the field of cardiac ablation.
脉冲场消融(PFA)是心律失常治疗中一种创新的能量输送方法,具有良好的安全性和有效的心肌病变形成。它已经证明了高的急性肺静脉分离率和降低了相邻解剖结构损伤的发生率。尽管如此,手术特异性并发症如溶血、血管内气体形成和冠状血管痉挛已被观察到,需要进一步评估。临床证据支持在心律失常复发方面与传统热消融相当的疗效。导管工程、脉冲调制和多模态能量策略的持续进步旨在增强病变的持久性和跨壁性。这些发展使PFA成为心脏消融领域的一项有前途的技术。
{"title":"Pulsed field ablation: The basics relating to effectiveness, durability, and safety","authors":"Sara Vázquez-Calvo,&nbsp;Deepti Ranganathan,&nbsp;Atul Verma","doi":"10.1016/j.pcad.2025.05.007","DOIUrl":"10.1016/j.pcad.2025.05.007","url":null,"abstract":"<div><div><span>Pulsed field ablation (PFA) represents an innovative energy delivery approach for cardiac arrhythmia treatment, characterized by a favorable safety profile and effective </span>myocardial lesion<span><span> formation. It has demonstrated high acute pulmonary vein isolation<span> rates with a reduced incidence of injury to adjacent </span></span>anatomical structures<span>. Nonetheless, procedure-specific complications such as haemolysis, intravascular gas formation, and coronary vasospasm<span> have been observed and warrant further evaluation. Clinical evidence supports efficacy comparable to conventional thermal ablation in terms of arrhythmia recurrence. Ongoing advancements in catheter engineering, pulse modulation, and multimodal energy strategies aim to enhance lesion durability and transmurality. These developments position PFA as a promising technology in the field of cardiac ablation.</span></span></span></div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 38-48"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac implantable electronic devices in pediatric and congenital populations 儿童和先天性人群心脏植入式电子装置。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.05.005
Douglas Y. Mah, John K. Triedman
Pediatric patients and children and adults with congenital heart disease often will require implantation of cardiac implantable electronic devices (CIEDs) for management of a variety of cardiac rhythm pathologies. The safe and effective use of CIEDs in these patients requires an awareness of important differences between this special population and the adult populations for whom these devices were primarily developed and in whom they have been most thoroughly studied. These include issues of body size and growth, anticipated lifespan, anatomical issues related to implantation and the epidemiology of underlying rhythm issues. In this paper, we discuss these issues in the context of the current state of the art in pediatric and congenital heart disease patients with respect to implant and lead extraction strategies, physiological cardiac pacing and resynchronization, ICD indications and use of transvenous and subcutaneous devices, and the use of implantable monitoring devices.
儿科患者和患有先天性心脏病的儿童和成人通常需要植入心脏植入式电子装置(cied)来治疗各种心律病变。在这些患者中安全有效地使用cied需要认识到这一特殊人群与成年人群之间的重要差异,成年人群主要是为这些设备开发的,并且对这些设备进行了最彻底的研究。这些问题包括身体大小和生长、预期寿命、与植入相关的解剖学问题以及潜在节律问题的流行病学问题。在本文中,我们讨论了这些问题在目前的背景下,在儿童和先天性心脏病患者的植入物和铅提取策略,生理心脏起搏和再同步,ICD指征和使用经静脉和皮下装置,以及使用植入式监测装置。
{"title":"Cardiac implantable electronic devices in pediatric and congenital populations","authors":"Douglas Y. Mah,&nbsp;John K. Triedman","doi":"10.1016/j.pcad.2025.05.005","DOIUrl":"10.1016/j.pcad.2025.05.005","url":null,"abstract":"<div><div><span><span>Pediatric patients and children and adults with congenital heart disease often will require implantation of cardiac implantable electronic devices (CIEDs) for management of a variety of cardiac rhythm pathologies. The safe and effective use of CIEDs in these patients requires an awareness of important differences between this special population and the adult populations for whom these devices were primarily developed and in whom they have been most thoroughly studied. These include issues of body size and growth, anticipated lifespan, anatomical issues related to implantation and the </span>epidemiology of underlying rhythm issues. In this paper, we discuss these issues in the context of the current state of the art in </span>pediatric and congenital heart disease patients with respect to implant and lead extraction strategies, physiological cardiac pacing and resynchronization, ICD indications and use of transvenous and subcutaneous devices, and the use of implantable monitoring devices.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 121-129"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Catheter ablation as first line therapy for atrial fibrillation 导管消融作为房颤的一线治疗。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2025.07.009
Maham F. Karatela, Hugh Calkins
The treatment for atrial fibrillation has evolved significantly over time. Previously, medication management was the mainstay of treatment. As we have developed more robust technologies and modalities for catheter ablation, these treatment recommendations have changed. Catheter ablation is a safe and effective strategy for treating atrial fibrillation that is now considered first-line therapy in some patient populations. In this review, we discuss historical perspectives regarding the treatment and management of atrial fibrillation. We review the literature on studies investigating catheter ablation as first-line therapy, including the impact of catheter ablation on arrhythmia recurrence, cardiovascular outcomes, and healthcare utilization. Finally, we discuss future directions for the management of atrial fibrillation as the technology for catheter ablation continues to grow and progress.
随着时间的推移,房颤的治疗已经发生了显著的变化。以前,药物管理是治疗的主要手段。随着我们开发出更强大的导管消融技术和模式,这些治疗建议也发生了变化。导管消融是一种安全有效的治疗心房颤动的策略,目前在一些患者群体中被认为是一线治疗。在这篇综述中,我们讨论了关于房颤治疗和管理的历史观点。我们回顾了导管消融作为一线治疗的研究文献,包括导管消融对心律失常复发、心血管结局和医疗保健利用的影响。最后,我们讨论了随着导管消融技术的不断发展和进步,心房颤动治疗的未来方向。
{"title":"Catheter ablation as first line therapy for atrial fibrillation","authors":"Maham F. Karatela,&nbsp;Hugh Calkins","doi":"10.1016/j.pcad.2025.07.009","DOIUrl":"10.1016/j.pcad.2025.07.009","url":null,"abstract":"<div><div>The treatment for atrial fibrillation has evolved significantly over time. Previously, medication management was the mainstay of treatment. As we have developed more robust technologies and modalities for catheter ablation, these treatment recommendations have changed. Catheter ablation is a safe and effective strategy for treating atrial fibrillation that is now considered first-line therapy in some patient populations. In this review, we discuss historical perspectives regarding the treatment and management of atrial fibrillation. We review the literature on studies investigating catheter ablation as first-line therapy, including the impact of catheter ablation on arrhythmia recurrence, cardiovascular outcomes, and healthcare utilization. Finally, we discuss future directions for the management of atrial fibrillation as the technology for catheter ablation continues to grow and progress.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 33-37"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword Omega-3与房颤风险:迷走神经介导的双刃剑。
IF 7.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.pcad.2024.11.003
Evan L. O'Keefe , James H. O'Keefe , Hussam Abuissa , Mark Metzinger , Ellen Murray , Grant Franco , Carl J. Lavie , William S. Harris

Objective

Studies regarding effects of omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on risk of atrial fibrillation (AF) have reported discordant results. The aim of this review is to clarify effects of marine omega-3 intake on risk of AF.

Patients and methods

A PubMed search was performed using terms: atrial fibrillation, omega-3, EPA, DHA, vagal tone. We summarized findings from randomized clinical trials (RCTs), epidemiology studies, and meta-analyses evaluating effects/associations of DHA + EPA on risk of AF. Also, vagal tone was explored as a mediator between omega-3 and risk of AF.

Results

Meta-analyses of 8 RCTs and 17 prospective cohort studies comprised of 83,112 and 54,799 individuals, respectively, investigated the link between omega-3 intake and incident AF. The RCTs reported that treatment with DHA and/or EPA was associated with a 24 % increased relative risk of AF (absolute risk 4.0 % vs 3.3 %; relative risk [RR] 1.24, 95 % confidence interval [CI] 1.11–1.38, p = 0.0002). This was dose-dependent; DHA + EPA doses of ∼1000 mg/d increased AF risk ∼12 %, whereas 1800 to 4000 mg/d increased AF risk by ∼50 %. In contrast, observational studies focused on DHA + EPA blood levels or dietary intake have generally reported that higher omega-3 levels/consumption are associated with lower AF risk. Maximal AF risk reduction.
(12 %) occurred at ∼650 mg/d of dietary DHA + EPA. Other studies have indicated that omega-3 fatty acids can dose-dependently increase vagal tone, which could explain the biphasic relationship between DHA + EPA and AF risk. Experimental studies show that low-level vagal stimulation decreases risk of AF, whereas high-level vagal stimulation increases risk of AF.

Conclusion

Higher consumption of dietary omega-3 is associated with decreased AF risk. In contrast, pharmaceutical dosing of omega-3 increases AF in a dose-dependent manner, which may be mediated by vagal tone.
目的:关于ω -3脂肪酸,特别是二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)对房颤(AF)风险影响的研究报告结果不一致。本综述的目的是阐明海洋摄入omega-3对房颤风险的影响。患者和方法:PubMed检索使用术语:心房颤动,omega-3, EPA, DHA,迷走神经张力。我们总结了随机临床试验(rct)、流行病学研究和评估DHA + EPA对房颤风险的影响/关联的荟萃分析的结果。此外,迷走神经张力作为omega-3与房颤风险之间的中介进行了探讨。8项随机对照试验和17项前瞻性队列研究的荟萃分析,分别包括83,112和54,799人,调查了ω -3摄入量与AF事件之间的联系。随机对照试验报告称,DHA和/或EPA治疗与AF相对风险增加24% %相关(绝对风险4.0 % vs 3.3 %;相对危险度[RR] 1.24, 95 %置信区间[CI] 1.11-1.38, p = 0.0002)。这是剂量依赖性的;DHA + EPA剂量为~1000 mg/d使房颤风险增加~12 %,而1800 ~ 4000 mg/d使房颤风险增加~50 %。相反,关注DHA + EPA血液水平或饮食摄入的观察性研究普遍报道,较高的omega-3水平/摄入与较低的房颤风险相关。最大限度降低房颤风险。(12 %)发生在~650 mg/d的膳食DHA + EPA。其他研究表明,omega-3脂肪酸可以剂量依赖性地增加迷走神经张力,这可以解释DHA + EPA与房颤风险之间的双相关系。实验研究表明,低水平的迷走神经刺激可降低AF的风险,而高水平的迷走神经刺激可增加AF的风险。结论:饮食中摄入更多的omega-3与降低AF的风险有关。相反,药物剂量的omega-3增加心房颤动以剂量依赖的方式,这可能是由迷走神经张力介导的。
{"title":"Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword","authors":"Evan L. O'Keefe ,&nbsp;James H. O'Keefe ,&nbsp;Hussam Abuissa ,&nbsp;Mark Metzinger ,&nbsp;Ellen Murray ,&nbsp;Grant Franco ,&nbsp;Carl J. Lavie ,&nbsp;William S. Harris","doi":"10.1016/j.pcad.2024.11.003","DOIUrl":"10.1016/j.pcad.2024.11.003","url":null,"abstract":"<div><h3>Objective</h3><div>Studies regarding effects of omega-3 fatty acids, specifically eicosapentaenoic acid<span><span> (EPA) and docosahexaenoic acid (DHA), on risk of </span>atrial fibrillation (AF) have reported discordant results. The aim of this review is to clarify effects of marine omega-3 intake on risk of AF.</span></div></div><div><h3>Patients and methods</h3><div><span>A PubMed<span> search was performed using terms: atrial fibrillation, omega-3, EPA, DHA, </span></span>vagal tone<span>. We summarized findings from randomized clinical trials<span> (RCTs), epidemiology studies, and meta-analyses evaluating effects/associations of DHA + EPA on risk of AF. Also, vagal tone was explored as a mediator between omega-3 and risk of AF.</span></span></div></div><div><h3>Results</h3><div><span>Meta-analyses of 8 RCTs and 17 prospective cohort studies comprised of 83,112 and 54,799 individuals, respectively, investigated the link between omega-3 intake and incident AF. The RCTs reported that treatment with DHA and/or EPA was associated with a 24 % increased relative risk of AF (absolute risk 4.0 % vs 3.3 %; relative risk [RR] 1.24, 95 % confidence interval [CI] 1.11–1.38, </span><em>p</em><span> = 0.0002). This was dose-dependent; DHA + EPA doses of ∼1000 mg/d increased AF risk ∼12 %, whereas 1800 to 4000 mg/d increased AF risk by ∼50 %. In contrast, observational studies focused on DHA + EPA blood levels or dietary intake have generally reported that higher omega-3 levels/consumption are associated with lower AF risk. Maximal AF risk reduction.</span></div><div>(12 %) occurred at ∼650 mg/d of dietary DHA + EPA. Other studies have indicated that omega-3 fatty acids can dose-dependently increase vagal tone, which could explain the biphasic relationship between DHA + EPA and AF risk. Experimental studies show that low-level vagal stimulation decreases risk of AF, whereas high-level vagal stimulation increases risk of AF.</div></div><div><h3>Conclusion</h3><div>Higher consumption of dietary omega-3 is associated with decreased AF risk. In contrast, pharmaceutical dosing of omega-3 increases AF in a dose-dependent manner, which may be mediated by vagal tone.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 3-9"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Progress in cardiovascular diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1